RWB
ANIP icon

RMR Wealth Builders’s ANI Pharmaceuticals ANIP Stock Holding History

RMR Wealth Builders’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-166
Closed -$6K – 199
2021
Q1 		$6K Buy
+166
New +$5.2K ﹤0.01% 645

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

RMR Wealth Builders's ANIP Position: Q2 2021 in Review

RMR Wealth Builders sold out of ANI Pharmaceuticals (ANIP) in Q2 2021, closing a stake of 166 shares — an estimated $6K sold.

RMR Wealth Builders first reported a position in ANIP in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 116 funds tracked by Wall St. Rank hold ANIP as of Q2 2021.

  • RMR Wealth Builders reported no remaining ANI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • RMR Wealth Builders sold 166 ANI Pharmaceuticals shares in Q2 2021, an estimated $6K.
  • RMR Wealth Builders first reported a position in ANI Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • RMR Wealth Builders's ANI Pharmaceuticals position peaked at $6K in Q1 2021.
  • 116 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2021.

Based on RMR Wealth Builders's 13F filing for Q2 2021, filed 16 Aug 2021.